ICUI
ICU Medical, Inc
Q3 2024 Conference Call
Presentation
November 12, 2024
Disclosures
2
2023-2024 Adjusted Revenue
In $ millions, unaudited
3
Together Announce
Joint Venture to Bolster IV Solutions Manufacturing and Innovation in the North American Market
Nov. 12, 2024
Otsuka Group Profile
Founded in 1921, Otsuka is a leading manufacturer of IV solutions outside North America and pharmaceutical products globally, aiming to create innovative products that meet a variety of clinical needs.
Otsuka Holdings
CY2023 Financial Overview
Market Capitalization (Nov. 2024)
~$33 Billion
Revenues
$14.2 Billion
Otsuka
(OPF)
Otsuka
(OPC)
Pharmaceutical
Pharmaceutical
Factory, Inc.
Co., Ltd.
Core Pharmaceutical and Nutraceutical Businesses
From diagnosis and treatment of disease to
maintaining and improving daily life
Otsuka Foods
Otsuka
Medical
Devices
Otsuka Chemical
Taiho
Pharmaceutical
Otsuka Warehouse
Business Profit1
$2.2 Billion
North American Revenues
~43%
Capital Expenditures
$1.5 Billion
Cash and Cash Equivalents
$3.6 Billion
Interest-bearing Debt2
$1.5 Billion
Figures are calculated at ¥141.82 = US$1 (closing rate at the end of the period)
1 Business profit = Revenue − Cost of sales − SG&A expenses + Share of profit of associates− R&D expenses 2 Interest-bearing debt is the total of bonds and borrowings, and lease liabilities
Otsuka Track Record of Innovation and Full PVC-Free Portfolio
Admixture
Parenteral Nutrition: TPN
Parenteral Nutrition: PPN
Premix, Ready-to-Use
The world's first premix IV antibiotic kit that is easy to use, helps minimize microbial contamination risk, reduces workload, and saves time
Why Otsuka
Transaction
Highlights
ICU Medical was deeply attracted to Otsuka for a set of core reasons:
Key economic terms of the Joint Venture:
JV Becomes Part of Manufacturing Network with Scale and Redundancy
Creates one of the largest IV solutions manufacturing networks on the planet
~1.4B annual units of combined production
17 combined global manufacturing sites
Significant CapEx investment to support IV Solutions growth
Otsuka: A Strong, Like-Minded Partner with Valuable Experience
Financial Strength
Cultural Mindset
"Creating new products
for better health worldwide."
These words embody Otsuka's dedication to:
Otsuka is dedicated to cultivating a dynamic corporate culture and workplaces that reflect their vision as a healthcare company, finding ways to live in harmony with local communities and the natural environment while contributing to richer and healthier lives.
U.S. Partnership Experience
Otsuka & Bristol-Myers Squibb Co-developand co-commercializethe antipsychotic drug ABILIFY®
(1999-2015)
Otsuka & Lundbeck Co-developand co-commercializeseveral psychiatric and neurological drugs including ABILIFY MAINTENA®, ABILIFY ASIMTUFII® and REXULTI®
(2011-Present)
Transaction Structure Key Items
Joint Venture
Setup
Benefits to
ICU Medical Shareholders
Pro Forma
Financial Impact
Disclaimer
ICU Medical Inc. published this content on November 13, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 13, 2024 at 04:05:06.301.